Cardiologic safety of menopausal hormone therapies

Grzegorz Stachowiak; Tomasz Pertyński

eISSN: 2299-0038
ISSN: 1643-8876

Menopause Review/Przegląd Menopauzalny

Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Open access

6/2009
vol. 8

Send email

Copy url:

abstract:

Review paper

Cardiologic safety of menopausal hormone therapies

Grzegorz Stachowiak

,

Tomasz Pertyński

Przegląd Menopauzalny 2009; 6: 315-319

Online publish date: 2010/02/08

View full text Get citation

Cardiovascular diseases appear to be the most frequent concomitant illnesses of the menopausal period. They are not only the main reasons of women’s deaths in the Western countries but also the most serious (but fortunately rare) complications of menopausal hormone therapies (MHT). In this article some cardiovascular risk factors influencing circulatory complications of MHT together with authors’ point of view concerning therapeutic safety were discussed. A particular attention has been paid to the choice of proper progestogen what plays a crucial role in the area of MHT safety.

keywords:

Cardiologic safety of menopausal hormone therapies

Grzegorz Stachowiak , Tomasz Pertyński

menopause, cardiovascular diseases, hormonal therapy, progestins

Grzegorz Stachowiak

,

Tomasz Pertyński